Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

QR Code

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

Scott A McConnell,1 Dharmik N Desai,1 Sejal P Faldu,1 Marjie L Hard,2 Angela Y Wehr,3 Peter J Weiden,1 Lisa von Moltke3 1Medical Affairs, Alkermes, Inc., Waltham, MA, 2Nuventra Pharma Sciences, Durham, NC, 3Clinical Research, Alkermes, Inc., Waltham, MA, USAThe recent publication by Salzman et al1...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	McConnell SA, Desai DN, Faldu SP, Hard ML, Wehr AY, Weiden PJ, von Moltke L
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2017
Sujets:	aripiprazole aripiprazole lauroxil pharmacokinetics;long-acting injectables Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/8036fa34f015403b9c1b841a7c733a17
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
par: Citrome L, et autres
Publié: (2019)

Aripiprazole en el tratamiento sintomático del síndrome de Gilíes de la Tourette (enfermedad de los tics)
par: Miranda C,Marcelo, et autres
Publié: (2007)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

Aripiprazole for late-life schizophrenia
par: Jeffrey Rado, et autres
Publié: (2010)

DEVELOPMENT OF A SIMPLE AND SPECIFIC UHPLC ASSAY FOR THE DETERMINATION OF ARIPIPRAZOLE AND DEHYDROARDPDPRAZOLE IN RAT PLASMA
par: YENICELI UĞUR,DUYGU, et autres
Publié: (2015)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
par: Subramanian Madhusoodanan, et autres
Publié: (2008)

The Binding of Aripiprazole to Plasma Proteins in Chronic Renal Failure Patients
par: Kenshiro Hirata, et autres
Publié: (2021)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
par: Madera JJ, et autres
Publié: (2019)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
par: Salzman PM, et autres
Publié: (2017)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
par: Peters-Strickland T, et autres
Publié: (2016)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
par: Peters-Strickland T, et autres
Publié: (2019)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
par: Zhi P, et autres
Publié: (2018)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
par: Madera J, et autres
Publié: (2019)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®): a case report
par: Shao Q, et autres
Publié: (2015)

Optimization of Processing Parameters of Nanoemulsion Containing Aripiprazole Using Response Surface Methodology
par: Samiun WS, et autres
Publié: (2020)

Low-dose aripiprazole for refractory burning mouth syndrome
par: Umezaki Y, et autres
Publié: (2016)

Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
par: Sugawara Kikuchi Y, et autres
Publié: (2019)

A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
par: Sugawara H, et autres
Publié: (2016)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
par: Kishi T, et autres
Publié: (2016)

Comparación del efecto de la terapia prolongada con antipsicóticos atípicos o convencionales en la incidencia de diabetes mellitus 2: Revisión sistemática y metaanálisis
par: Sapunar Z,Jorge, et autres
Publié: (2009)

Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus
par: Kiss Alexander, et autres
Publié: (2020)

Aripiprazole augmentation in managing comorbid obsessive–compulsive disorder and bipolar disorder: a case with suicidal attempts
par: Lai J, et autres
Publié: (2016)

Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials
par: Luan SX, et autres
Publié: (2018)

c-Fos and FosB/ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences
par: Kiss Alexander, et autres
Publié: (2020)

Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation
par: Omori Y, et autres
Publié: (2018)

Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum
par: Kiss Alexander, et autres
Publié: (2019)

Haloperidol and aripiprazole impact on the BDNF and glucocorticoid receptor levels in the rat hippocampus and prefrontal cortex: effect of the chronic mild stress
par: Osacka Jana, et autres
Publié: (2021)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
par: Cuomo I, et autres
Publié: (2018)

COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
par: Kaneko H, et autres
Publié: (2018)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
par: Di Lorenzo R, et autres
Publié: (2019)

Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
par: Alsayouf HA, et autres
Publié: (2020)

Effect of aripiprazole on non-24-hour sleep–wake rhythm disorder comorbid with major depressive disorder: a case report
par: Matsui K, et autres
Publié: (2017)

Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors
par: De Santis M, et autres
Publié: (2018)

Atypical antipsychotics as add-on treatment in late-life depression
par: Cakir S, et autres
Publié: (2016)

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study
par: Kiss Alexander
Publié: (2018)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
par: Roganović Maša, et autres
Publié: (2021)

Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion
par: Veselinović T, et autres
Publié: (2018)

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
par: Gellért Balázs Karvaly, et autres
Publié: (2021)

A generic 89Zr labeling method to quantify the in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography
par: Li N, et autres
Publié: (2017)